SKAN Group AG
SIX:SKAN
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CH |
|
SKAN Group AG
SIX:SKAN
|
1.3B CHF |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
204.9B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
153.2B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.4B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
36.9B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
32B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.3B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.8B USD |
Loading...
|
Market Distribution
| Min | -57 027.8% |
| 30th Percentile | 1.3% |
| Median | 7.2% |
| 70th Percentile | 13.7% |
| Max | 3 663.7% |
Other Profitability Ratios
SKAN Group AG
Glance View
SKAN Group AG, headquartered in Switzerland, has carved out its niche as a leading innovator in the realm of contamination control for aseptic environments. The company's history traces back to its founding in 1968, following the rapid advancements in the pharmaceutical and biotechnology sectors. SKAN has since developed a sterling reputation for its pioneering work in isolator technology, offering solutions that ensure the highest standards of sterility and safety critical to these industries. The company designs and manufactures isolators, which are essentially sealed environments that provide contamination-free zones for the processing of materials or production of pharmaceuticals, ensuring that even the most sensitive products are handled with stringent safety measures. This focus on high-tech, specialized equipment forms the backbone of SKAN's revenue model. By providing bespoke solutions tailored to the unique requirements of its clients, SKAN taps into the lucrative markets of pharmaceutical production and research, biotechnology companies, and laboratories that demand high-performance contamination barriers. Beyond just the sale of equipment, SKAN also offers a comprehensive suite of services, including installation, validation, maintenance, and training, ensuring a steady flow of income as these businesses need continual updates and technical support for their critical infrastructure. The demand for stricter health regulations and more advanced pharmaceuticals continues to rise, positioning SKAN Group AG as a pivotal player in this essential industry, capitalizing on its expertise to ensure both safety and compliance for its customers worldwide.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for SKAN Group AG is 4.9%, which is below its 3-year median of 8.5%.
Over the last 3 years, SKAN Group AG’s Net Margin has increased from 2.7% to 4.9%. During this period, it reached a low of 2.7% on Jun 30, 2022 and a high of 10.7% on Dec 31, 2024.